| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -23,550 | -1,300 | -1,090 | -450 | 5,760 |
| Net Income Growth | -1,711.54% | -19.27% | -142.22% | -107.81% | +184.33% |
Purple Biotech Ltd ADR (PPBT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Purple Biotech Ltd. is a clinical-stage company focusing on therapies to overcome tumor immune evasion and drug resistance. The Company's oncology pipeline includes NT219 and CM24. Purple Biotech Ltd., formerly known as Kitov Pharma Ltd., is based in TEL AVIV, Israel.
Fiscal Year End Date: 12/31